arrow Log In to View Account     |          
UTASIP
UTASIP Logo

New Horizons for the Management of Hepatitis C: Pharmacist Perspectives

OVERVIEW
Hepatitis C virus (HCV) infection is an important national health issue that affects nearly 170 million people worldwide. Over 66% of affected individuals develop chronic infection, often leading to serious hepatic complications such as fibrosis, cirrhosis, and hepatocellular carcinoma. Associated with substantial morbidity and mortality, data indicate that HCV infection and its resultant complications are responsible for over 12 000 deaths each year. As such, it is imperative that patients at risk for HCV be adequately screened, as early diagnosis and treatment can help eradicate the virus and prevent disease progression. The following interactive monograph discusses HCV risk factors and predictors of virologic response as a result of HCV treatment and assesses the role of new and emerging treatments for patients with chronic HCV infection. In addition, the authors examine how to develop individualized management plans for patients who have failed to respond to a previous course of interferon-based therapy and methods for implementing an intervention to improve adherence to therapy for chronic HCV.

GOAL
To provide managed care pharmacists with up-to-date information regarding their role in managing patients with HCV.

INTENDED AUDIENCE
This activity is designed for managed care pharmacists. No prerequisites required.

LEARNING OBJECTIVES
The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity. At the conclusion of this activity, the participant should be able to:

  • List risk factors for chronic HCV infection to determine who should be screened.
  • Identify 2 important predictors of virologic response for treatment for chronic HCV infection.
  • Develop an individualized management plan for patients who have failed to respond to a previous course of interferon-based therapy.
  • Implement an intervention to improve adherence to therapy for chronic HCV infection.
  • Assess the role of new and emerging agents for the management of patients with chronic HCV infection.

ACCREDITATION STATEMENT
The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education to provide continuing education for pharmacists.

CREDIT DESIGNATION STATEMENT
acpe logoThe University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this knowledge-based educational activity will provide a statement for 1.5 contact hours credit (0.15 CEUs) and will be available for download following successful completion of the activity. Successful completion includes taking the pre-test, participating in the activity, completing a self-assessment instrument with a score of at least 70%, and completing an evaluation instrument. If you score less than 70% on the self-assessment instrument, you will be allowed to complete the examination one more time. ACPE Program #0064-0000-11-219-H01-P.

The estimated time to complete this educational activity: 1.5 hours.

Release date: August 31, 2011; Expiration date: August 31, 2012.

FULL DISCLOSURE POLICY AFFECTING CPE ACTIVITIES
As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Course Director and Participating Faculty reported the following:

Jason P. Smith, PharmD (Chair)
Department of Pharmacy
Greater Los Angeles Veterans Affairs Healthcare System
West Los Angeles VA Medical Center
Los Angeles, California
Dr Smith reports holding stock in Vertex Pharmaceuticals.

Pamela S. Belperio, PharmD, BCPS, AAHIVE
National Public Health Clinical Pharmacist
Center for Quality Management in Public Health
Department of Veterans Affairs
Los Angeles, California
Dr Belperio reports having no significant financial or advisory relationships with corporate organizations related to this activity.

Christine Pocha, MD, PhD
Assistant Professor of Medicine
University of Minnesota
Co-Director, Minneapolis Hepatitis C Resource Center
Staff Gastroenterologist, GI Department
Minneapolis VA Health Care System
Minneapolis, Minnesota
Dr Pocha reports serving as a consultant for Three Rivers Pharmaceuticals.

OFF-LABEL PRODUCT DISCUSSION
In accordance with ACPE Criteria for Quality, the audience is advised that authors in this CPE activity may include reference(s) to unlabeled, unapproved, or investigational uses of therapeutic agents or biomedical devices. The authors will inform the participants of when they discuss or reference an unapproved, unlabeled, or investigational use of therapeutic agent or biomedical device.

DISCLAIMER STATEMENT
The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of The University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.

GRIEVANCE POLICY
A participant, sponsor, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity sponsored or cosponsored by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing at gfarr@utasip.com. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.

FEE INFORMATION
There is no fee for this educational activity.

TABLE OF CONTENTS
Instructions: The following is an interactive activity designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited pre-test, a series of articles with case decision points, and a CPE post-test and evaluation. All 3 sections must be completed to receive CPE credit.

Pre-Test

New Horizons for the Management of Hepatitis C: Pharmacist Perspectives
Jason P. Smith, PharmD

Hepatitis C Infection and Burden of Disease
Christine Pocha, MD, PhD

Managing Hepatitis C Virus Infection: Examining the Evolving Treatment Landscape
Pamela S. Belperio, PharmD, BCPS, AAHIVE

The Need for Pharmacist Involvement in Managing Patients with Hepatitis C
Jason P. Smith, PharmD

Post-Test

Supported by an educational grant from Vertex Pharmaceuticals

procced to pretest
University of Tennessee Advanced Studies in Pharmacy (ISSN-1558-0350), is published by Galen Publishing, LLC, d/b/a ASiM, PO Box 340, Somerville, NJ 08876. (908) 253-9001. Copyright ©2015 by Galen Publishing. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. ASiM is a registered trademark of The Healthcare Media Group, LLC.